Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Receive $4.9M from Private Placement

NEW YORK, May 20 - CombiMatrix parent Acacia Research announced a private placement of 2.4 million units of its common stock today, out of which CombiMatrix will receive about $4.9 million.


The stock units, which include one share of Acacia Research-CombiMatrix stock and one-half warrant, are being purchased for $2.20 per unit, for a total of $5.28 million.


The company plans to use its funding to give it "the flexibility to take advantage of current opportunities," CEO Amit Kumar said in a statement.


CombiMatrix, founded in 1995, was funded with $36 million in August 2000. Acacia Research, which has since bought a majority stake of the company's equity, was the lead investor in the VC funding, anteing in $17.5 million with additional investments from a mix of Silicon Valleyand New Yorkventure capital investors.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.